Literature DB >> 3734629

Abnormal low density lipoprotein metabolism in apolipoprotein E deficiency.

C Gabelli, R E Gregg, L A Zech, E Manzato, H B Brewer.   

Abstract

Apolipoprotein(apo) E deficiency is an inherited disease characterized by type III hyperlipoproteinemia and less than 1% normal plasma apoE concentration. The role of apoE in LDL metabolism was investigated by quantitating the metabolism of radiolabeled normal and apoE-deficient LDL in both normal and apoE-deficient subjects. ApoE deficiency resulted in an accumulation of plasma IDL, and a decreased synthesis of LDL consistent with a block in the conversion of IDL to LDL. The LDL isolated from the apoE-deficient patient was similar to normal LDL in hydrated density, size, and composition. However, the apoE-deficient LDL was kinetically abnormal with delayed catabolism in both normal subjects and the apoE-deficient patient. In addition, the catabolism of normal LDL in the apoE-deficient subject was increased. These results were interpreted as indicating that apoE is necessary for the conversion of IDL to LDL and the formation of kinetically normal LDL. The rapid catabolism of normal LDL in the apoE-deficient patient suggests an up-regulation of the hepatic LDL receptor pathway. Based on these results, apoE is proposed to play an important role in the conversion of IDL to LDL, the formation of kinetically normal LDL, and the regulation of LDL receptor function.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3734629

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  9 in total

1.  Hypercholesterolemia and Dyslipidemia.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-04

2.  Lipoprotein lipase- and hepatic triglyceride lipase- promoted very low density lipoprotein degradation proceeds via an apolipoprotein E-dependent mechanism.

Authors:  J D Medh; G L Fry; S L Bowen; S Ruben; H Wong; D A Chappell
Journal:  J Lipid Res       Date:  2000-11       Impact factor: 5.922

3.  Integrated role of two apoliprotein E polymorphisms on apolipoprotein B levels and coronary artery disease in a biethnic population.

Authors:  Zeynep Ozturk; Byambaa Enkhmaa; Neil S Shachter; Lars Berglund; Erdembileg Anuurad
Journal:  Metab Syndr Relat Disord       Date:  2010-08-17       Impact factor: 1.894

4.  Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects.

Authors:  T Demant; D Bedford; C J Packard; J Shepherd
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

5.  Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption.

Authors:  S H Zhang; R L Reddick; B Burkey; N Maeda
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

6.  Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production.

Authors:  D J Rader; W Cain; L A Zech; D Usher; H B Brewer
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

7.  Hsa-miRNA-23a-3p promotes atherogenesis in a novel mouse model of atherosclerosis.

Authors:  Jiayan Guo; Hanbing Mei; Zhen Sheng; Qingyuan Meng; Murielle M Véniant; Hong Yin
Journal:  J Lipid Res       Date:  2020-10-02       Impact factor: 5.922

8.  Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III.

Authors:  Raimund Pechlaner; Sotirios Tsimikas; Xiaoke Yin; Peter Willeit; Ferheen Baig; Peter Santer; Friedrich Oberhollenzer; Georg Egger; Joseph L Witztum; Veronica J Alexander; Johann Willeit; Stefan Kiechl; Manuel Mayr
Journal:  J Am Coll Cardiol       Date:  2017-02-21       Impact factor: 24.094

Review 9.  The role of APOE4 in Alzheimer's disease: strategies for future therapeutic interventions.

Authors:  Holly C Hunsberger; Priyanka D Pinky; Warren Smith; Vishnu Suppiramaniam; Miranda N Reed
Journal:  Health Psychol Behav Med       Date:  2019-04-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.